Fundamental Analysis of ELEVAI LABS INC(NASDAQ:ELAB) stock

Fundamental Rating

Overall ELAB gets a fundamental rating of 3 out of 10. We evaluated ELAB against 36 industry peers in the Personal Care Products industry. No worries on liquidiy or solvency for ELAB as it has an excellent financial health rating, but there are worries on the profitability. ELAB is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year ELAB has reported negative net income.

In the past year ELAB has reported a negative cash flow from operations.

1.2 Ratios

With a Return On Assets value of -48.81%, ELAB is not doing good in the industry: 85.71% of the companies in the same industry are doing better.

ELAB has a worse Return On Equity (-63.92%) than 74.29% of its industry peers.

		Industry Rank	Sector Rank
ROA	-48.81%
ROE	-63.92%
ROIC	N/A

ROA(3y)-98.18%

ROA(5y)N/A

ROE(3y)-148.34%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

Looking at the Gross Margin, with a value of 71.15%, ELAB is in the better half of the industry, outperforming 68.57% of the companies in the same industry.

The Profit Margin and Operating Margin are not available for ELAB so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	71.15%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ELAB does not have a ROIC to compare to the WACC, probably because it is not profitable.

ELAB has less shares outstanding than it did 1 year ago.

ELAB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

ELAB has an Altman-Z score of -0.66. This is a bad value and indicates that ELAB is not financially healthy and even has some risk of bankruptcy.

ELAB has a worse Altman-Z score (-0.66) than 85.71% of its industry peers.

There is no outstanding debt for ELAB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-0.66

ROIC/WACCN/A

WACC9.21%

2.3 Liquidity

ELAB has a Current Ratio of 3.86. This indicates that ELAB is financially healthy and has no problem in meeting its short term obligations.

Looking at the Current ratio, with a value of 3.86, ELAB belongs to the top of the industry, outperforming 85.71% of the companies in the same industry.

A Quick Ratio of 3.40 indicates that ELAB has no problem at all paying its short term obligations.

ELAB has a Quick ratio of 3.40. This is amongst the best in the industry. ELAB outperforms 88.57% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	3.86
Quick Ratio	3.4

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

ELAB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -49543.54%.

The Revenue has grown by 122.42% in the past year. This is a very strong growth!

EPS 1Y (TTM)-49543.54%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-29884.05%

Revenue 1Y (TTM)122.42%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%-4.9%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

ELAB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for ELAB!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ELEVAI LABS INC

NASDAQ:ELAB (12/20/2024, 8:06:55 PM)

After market: 2.53 -0.03 (-1.17%)

2.56

+0.21 (+8.94%)

Chartmill FA Rating

GICS SectorConsumer Staples

GICS IndustryGroupHousehold & Personal Products

GICS IndustryPersonal Care Products

Earnings (Last)N/A N/A

Earnings (Next)N/A N/A

Inst Owners104.94%

Inst Owner Change1690.43%

Ins Owners489.3%

Ins Owner Change0%

Market Cap6.63M

AnalystsN/A

Price TargetN/A

Short Float %N/A

Short Ratio0

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)N/A

PT rev (3m)N/A

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	2.71
P/FCF	N/A
P/OCF	N/A
P/B	0.78
P/tB	1.16
EV/EBITDA	N/A

EPS(TTM)-45.18

EYN/A

EPS(NY)N/A

Fwd EYN/A

FCF(TTM)-2.33

FCFYN/A

OCF(TTM)-2.27

OCFYN/A

SpS0.94

BVpS3.3

TBVpS2.21

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-48.81%
ROE	-63.92%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	71.15%
FCFM	N/A

ROA(3y)-98.18%

ROA(5y)N/A

ROE(3y)-148.34%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score4

Asset Turnover0.22

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	1357.72%
Cap/Sales	7.01%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	3.86
Quick Ratio	3.4
Altman-Z	-0.66

F-Score4

WACC9.21%

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-49543.54%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-29884.05%

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)122.42%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%-4.9%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-110.06%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-180.24%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-186.59%

OCF growth 3YN/A

OCF growth 5YN/A

ELEVAI LABS INC (ELAB)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens